Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.38 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | TYK2 | P29597 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.32 |
| ▸ | TYRO3 | Q06418 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 2/20 | 0.31 |
| ▸ | CDK9 | P50750 | 2/20 | 0.31 |
| ▸ | AXL | P30530 | 1/20 | 0.31 |
| ▸ | FLT3 | P36888 | 1/20 | 0.31 |
| ▸ | MERTK | Q12866 | 1/20 | 0.31 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25673249 | 0.93 | JAK2 (0.38) | JAK2JAK1TYK2JAK3MAPK8 | |
| SCHEMBL31160713 | 0.88 | JAK2 (0.35) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL23233965 | 0.88 | JAK2 (0.36) | JAK2JAK1TYK2JAK3CD274 | |
| SCHEMBL31160742 | 0.87 | CCNE1 (0.37) | JAK2JAK1TYK2JAK3CDK2 | |
| SCHEMBL23209372 | 0.87 | CCNE1 (0.42) | JAK2JAK1JAK3CDK2CDK9 | |
| SCHEMBL31423986 | 0.87 | JAK2 (0.36) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL31423979 | 0.84 | JAK2 (0.37) | JAK2JAK1TYK2JAK3 | |
| SCHEMBL31160925 | 0.84 | ALDH1A1 (0.37) | JAK2JAK1JAK3MAPK8CDK2 | |
| SCHEMBL31423960 | 0.83 | JAK2 (0.38) | JAK2JAK1TYK2JAK3LRRK2 | |
| SCHEMBL25272284 | 0.82 | JAK2 (0.36) | JAK2JAK1TYK2JAK3LRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4673449-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | Differentiated Therapeutics Inc (US) | 2026-01-07 | — | — | EP | disclosed |
| WO-2024182555-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS, INC. (US) | 2024-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260062426-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CCNA1, CCNE1, CCNA2 | JAK2 1817/4885JAK1 866/4885TYK2 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.